We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
Read MoreHide Full Article
Myriad Genetics, Inc. (MYGN - Free Report) entered into a non-exclusive collaboration with Personalis through which Myriad will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners. Financial terms of the deal were not disclosed.
The collaboration will expand Myriad Genetics pharma services.
More on the News
Personalis' ImmunoID NeXT technology, which the top 20 worldwide biopharma companies have used, is the most discriminating platform for powering drug development biomarker initiatives. It offers high-quality exome/transcriptome assays for FFPE cancer tissues.
Strategic Efforts
Several companion diagnostic pharmaceutical partners are requesting whole exome and whole transcriptome testing on the tumors of their patients. Myriad Genetics' goal is to provide its customers with complete menu access and the company is thrilled to enhance its offering by leveraging Personalis' high-quality assays.
Through this collaboration, partners will utilize the MyRisk Hereditary Cancer Test, BRACAnalysis CDx and/or MyChoiceCDx cancer tests.
Industry Prospects
Per a report by Reports And Data, the global precision oncology market is expected to reach $99.72 billion in 2027 from $49.98 billion in 2019 at a CAGR of 9.9%. Factors like rising cancer incidences and growing awareness pertaining to molecular-level diagnosis and treatment are likely to drive the market for the same.
Progress Within Testing Menu
During third-quarter earnings update, Myriad Genetics talked about continuous gain in share in the hereditary cancer market, with volumes rising 18% year over year in the third quarter. This was driven by competitive account wins and increased adoption by providers of myRisk.
Image Source: Zacks Investment Research
In the third quarter, hereditary cancer testing volumes from the oncology business rose 15% year over year, well above the estimated industry growth, reflecting enduring franchise and improving its brand reputation. Prolaris — the prostate cancer test — continued its momentum, with third-quarter revenues up 18% year over year.
In September 2023, Myriad Genetics announced two key milestones in its strategic partnership with Illumina. The collaboration brings together Myriad’s MyChoice CDx homologous recombination deficiency (HRD) technology and Illumina’s expertise in comprehensive genomic profiling to broaden clinical research opportunities and drive CDx development for gene-based therapies.
Price Performance
In the past year, MYGN’s shares have declined 7.6% compared with the industry’s fall of 25%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
Myriad Genetics, Inc. (MYGN - Free Report) entered into a non-exclusive collaboration with Personalis through which Myriad will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners. Financial terms of the deal were not disclosed.
The collaboration will expand Myriad Genetics pharma services.
More on the News
Personalis' ImmunoID NeXT technology, which the top 20 worldwide biopharma companies have used, is the most discriminating platform for powering drug development biomarker initiatives. It offers high-quality exome/transcriptome assays for FFPE cancer tissues.
Strategic Efforts
Several companion diagnostic pharmaceutical partners are requesting whole exome and whole transcriptome testing on the tumors of their patients. Myriad Genetics' goal is to provide its customers with complete menu access and the company is thrilled to enhance its offering by leveraging Personalis' high-quality assays.
Through this collaboration, partners will utilize the MyRisk Hereditary Cancer Test, BRACAnalysis CDx and/or MyChoiceCDx cancer tests.
Industry Prospects
Per a report by Reports And Data, the global precision oncology market is expected to reach $99.72 billion in 2027 from $49.98 billion in 2019 at a CAGR of 9.9%. Factors like rising cancer incidences and growing awareness pertaining to molecular-level diagnosis and treatment are likely to drive the market for the same.
Progress Within Testing Menu
During third-quarter earnings update, Myriad Genetics talked about continuous gain in share in the hereditary cancer market, with volumes rising 18% year over year in the third quarter. This was driven by competitive account wins and increased adoption by providers of myRisk.
In the third quarter, hereditary cancer testing volumes from the oncology business rose 15% year over year, well above the estimated industry growth, reflecting enduring franchise and improving its brand reputation. Prolaris — the prostate cancer test — continued its momentum, with third-quarter revenues up 18% year over year.
In September 2023, Myriad Genetics announced two key milestones in its strategic partnership with Illumina. The collaboration brings together Myriad’s MyChoice CDx homologous recombination deficiency (HRD) technology and Illumina’s expertise in comprehensive genomic profiling to broaden clinical research opportunities and drive CDx development for gene-based therapies.
Price Performance
In the past year, MYGN’s shares have declined 7.6% compared with the industry’s fall of 25%.
Zacks Rank and Key Picks
Myriad Genetics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DexCom (DXCM - Free Report) . While Haemonetics and DexCom carry a Zacks Rank #2 (Buy), Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.